Ultragenyx Pharmaceutical (NASDAQ:RARE) Coverage Initiated by Analysts at Royal Bank of Canada

Royal Bank of Canada began coverage on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) in a report released on Monday, Marketbeat.com reports. The brokerage issued an outperform rating and a $77.00 price target on the biopharmaceutical company’s stock. Several other equities analysts have also recently commented on RARE. JPMorgan Chase & Co. upped their […]

Related Keywords

United States ,Canada ,Arizona ,Japan ,America ,Robertw Baird ,Karah Herdman Parschauer ,Royal Bank ,Allspring Global Investments Holdings ,Securities Exchange Commission ,Covestor Ltd ,Associates Corp ,Nasdaq ,Cantor Fitzgerald ,Jpmorgan Chase Co ,Canaccord Genuity Group ,Ultragenyx Pharmaceutical Inc ,Ultragenyx Pharmaceutical ,Free Report ,Genuity Group ,Moderate Buy ,Get Free Report ,John Richard Pinion ,Exchange Commission ,Herdman Parschauer ,State Retirement System ,Global Investments Holdings ,Pharmaceutical Inc ,North America ,Latin America ,Ultragenyx Pharmaceutical Daily ,